Antibiotics exposure and risk of inflammatory bowel disease: a systematic review

Theochari, Nikoletta A; Stefanopoulos, Anastasios; Mylonas, Konstantinos S.; Economopoulos, Konstantinos P.

doi:10.1080/00365521.2017.1386711

Cited by 65 publications

(37 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antibiotic exposure has increasingly been associated with subsequent development of chronic conditions, including IBD. 19,[21][22][23][24] Metronidazole and ciprofloxacin are the most commonly used antibiotics in the clinic to induce remission of IBD. 12,13 They are also the most associated with a subsequent diagnosis of IBD, although all antibiotics tested showed an association, with the exception of penicillin.…”

Section: Discussionmentioning

confidence: 99%

“…[19][20][21][22][23][24] Although some of these associations are related to paediatric-onset IBD, 22 the case is equally strong for adult-onset IBD. 19,23,24 Interestingly, one study suggested that the strongest association for antimicrobial treatment with subsequent IBD diagnosis was for the Abx that are used to treat the disease itself: metronidazole and fluoroquinalones, of which ciprofloxacin is a family member. 24 Poor health outcomes following Abx exposure, especially early in life, appear to also diverge by sex.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sexual Dimorphism in the Response to Broad-spectrum Antibiotics During T Cell-mediated Colitis

Harrison

Laubitz

Midura-Kiela

et al. 2018

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Sexual Dimorphism in the Response to Broad-spectrum Antibiotics During T Cell-mediated Colitis

Harrison

Laubitz

Midura-Kiela

et al. 2018

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

show abstract

“…The use of doxycycline has been associated with an increased risk of developing irritable bowel diseases (IBS) and inflammatory bowel diseases (IBD). 34 – 36 In a large retrospective study, patients who were prescribed doxycycline for their acne had a 2.25-fold greater risk of developing Crohn’s disease. 35 Rare but significant systemic AEs have occurred primarily with the use of minocycline.…”

Section: Side Effects Among Broad-spectrum Tetracyclinesmentioning

confidence: 99%

<p>Sarecycline: A Review of Preclinical and Clinical Evidence</p>

Moore¹,

Rosso²,

Johnson³

et al. 2020

CCID

View full text Add to dashboard Cite

Sarecycline is a tetracycline-derived oral antibiotic, specifically designed for acne, and is approved by the Food and Drug Administration (FDA) in 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris (AV) in patients 9 years of age and older. It has been decades since a novel systemic antibiotic was approved to treat AV, a disease that affects up to 90% of teenagers and young adults worldwide and lasts well into adulthood. Sarecycline holds promise to yield fewer side effects than other commonly used broad-spectrum tetracyclines, including minocycline and doxycycline. The narrower spectrum of antibacterial activity of sarecycline, which specifically targets C. acnes and some Gram-positive bacteria with little or no activity against Gram-negative bacteria, suggests not only the potential for reduced emergence of antibiotic-resistant bacterial strains but also less disruption of the human gut microflora. Here, we review the key preclinical and clinical evidence on sarecycline.

show abstract

“…Exposure to antibiotics during pregnancy or early childhood can cause severe disruption to the developing microbiome and an increased risk of dysbiosis and IBD, particularly CD [ 65 , 66 , 67 , 68 ]. However, some studies suggest that antibiotics given antepartum or postpartum do not alter IBD risk in offspring [ 36 , 69 ].…”

Section: Influences On Colonizationmentioning

confidence: 99%

Inflammatory Bowel Diseases: Host-Microbial-Environmental Interactions in Dysbiosis

2020

View full text Add to dashboard Cite

Crohn’s Disease (CD) and Ulcerative Colitis (UC) are world-wide health problems in which intestinal dysbiosis or adverse functional changes in the microbiome are causative or exacerbating factors. The reduced abundance and diversity of the microbiome may be a result of a lack of exposure to vital commensal microbes or overexposure to competitive pathobionts during early life. Alternatively, many commensal bacteria may not find a suitable intestinal niche or fail to proliferate or function in a protective/competitive manner if they do colonize. Bacteria express a range of factors, such as fimbriae, flagella, and secretory compounds that enable them to attach to the gut, modulate metabolism, and outcompete other species. However, the host also releases factors, such as secretory IgA, antimicrobial factors, hormones, and mucins, which can prevent or regulate bacterial interactions with the gut or disable the bacterium. The delicate balance between these competing host and bacteria factors dictates whether a bacterium can colonize, proliferate or function in the intestine. Impaired functioning of NOD2 in Paneth cells and disrupted colonic mucus production are exacerbating features of CD and UC, respectively, that contribute to dysbiosis. This review evaluates the roles of these and other the host, bacterial and environmental factors in inflammatory bowel diseases.

show abstract

Antibiotics exposure and risk of inflammatory bowel disease: a systematic review

Cited by 65 publications

References 29 publications

Sexual Dimorphism in the Response to Broad-spectrum Antibiotics During T Cell-mediated Colitis

Sexual Dimorphism in the Response to Broad-spectrum Antibiotics During T Cell-mediated Colitis

<p>Sarecycline: A Review of Preclinical and Clinical Evidence</p>

Inflammatory Bowel Diseases: Host-Microbial-Environmental Interactions in Dysbiosis

Contact Info

Product

Resources

About